[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581520":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":51,"collaborators":21,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":21,"enrollmentInfo":63,"targetDuration":21,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":35,"whyStopped":21,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"IRCCS Eugenio Medea","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Expanding NGS data with Optical Genome Mapping (OGM)","EXPERIMENTAL","OGM will be used alongside WGS to improve diagnostics in 60 children with severe NDDs lacking a molecular diagnosis after initial CMA and exome analyses.",[13,14],"Genetic: Optical Genome Mapping (OGM) and Whole Genome Sequencing (WGS)","Other: Trascriptome analysis",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"GENETIC","Optical Genome Mapping (OGM) and Whole Genome Sequencing (WGS)","After identifying causal SVs via OGM, WGS will determine rearrangement breakpoints and examine nearby genes within 100 kb that may have altered expression due to positional effects.",[9],null,{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Trascriptome analysis","Following genomic characterization results, transcriptome analysis will be performed on patient-derived lymphoblastoid B-cell lines or fibroblasts to investigate the molecular implications of candidate SVs found in the OGM analysis and identify potential transcriptome abnormalities, such as splicing variants, in patients with atypical clinical features.",[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":21,"email":31},"Maria Clara Bonaglia PhD","CONTACT","+39 031 877913","mariaclara.bonaglia@lanostrafamiglia.it",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Cytogenetic Unit of Medical Genetic Laboratory","RECRUITING","Bosisio Parini","Lecco","23842","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],9.29,45.80075,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":21,"email":21},"Maria C Bonaglia, Master Degree","+39 031877913",{"type":52,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100581520","expanding-ngs-data-with-optical-genome-mapping-ogm-100581520",false,"NCT06851377","Expanding NGS Data with Optical Genome Mapping (OGM)","Expanding NGS Data with Optical Genome Mapping (OGM): More Comprehensive Variant Detection in Children with Unexplained Rare Genetic Disorders","OGM","Inclusion Criteria:\n\n* individuals without a molecular diagnosis (negative to ES\u002FCMA analyses);\n* individuals with genetic diagnoses that explain only one component of their primary phenotype;\n* individuals carrying one or more variants of uncertain clinical significance\n* individuals with a phenotype highly reminiscent of clinically and molecularly well-defined syndromes (i.e., Marfan Syndrome) but negative to routine molecular analysis.\n\nExclusion Criteria:\n\n* individuals who have not undergone initial diagnostic genetic tests (ES\u002FCMA)","ALL","2 Years",{"count":64,"type":65},60,"ESTIMATED","INTERVENTIONAL",[68],"NA","Over 50% of pediatric neurological and neurodevelopmental disorders lack a molecular diagnosis after standard DNA sequencing and molecular karyotyping. This is due to technical limitations, incomplete variant interpretation, and inadequate genotype-phenotype correlations. New sequencing technologies are crucial for clinical decision-making, offering complete profiles of variants in a patient's DNA to personalize treatment. Optical Genome Mapping (OGM) can detect nearly all structural variants in one experiment. This project aims to use OGM alongside NGS to improve diagnostic yield in 60 children with severe disorders who tested negative for NGS\u002FCMA.",[71],"Neurodevelopmental Disorder (Diagnosis)",[73],"Optical Genome Mapping, neurodevelopmental disorders, genome sequencing","2025-02-24",{"date":76,"type":77},"2025-02-28","ACTUAL",{"date":79,"type":77},"2024-05-23",{"date":81,"type":65},"2026-12",{"name":5,"class":6},1]